title: Effect of once-daily FDC treatment era on initiation of cART.
abstract: OBJECTIVE
  Combination antiretroviral therapy (cART) is associated with increased survival among HIV-infected persons. Yet, no research to date has examined whether introduction of once-daily fixed-dosed combinations (FDC) affects the likelihood of cART initiation. We aimed to determine whether implementation of once-daily FDC regimens was associated with changes to cART initiation. We also identified clinical, treatment regimen, and provider characteristics possibly associated with cART initiation.
  
  
  METHODS
  Retrospective observational analysis.
  
  
  METHODS
  We queried electronic medical records between July 1999-June 2006 to identify incident cases of detectable HIV infection in antiretroviral-naïve adults. Cox regression with time-dependent covariates was used to examine the effects of once-daily FDC era, clinical, provider, and treatment regimen characteristics on cART initiation.
  
  
  RESULTS
  Once-daily FDC availability did not change the likelihood of cART initiation, but other characteristics were associated with an increased likelihood: AIDS diagnosis, above-median daily pill consumption, and 16+ yrs of physician HIV experience. Decreased likelihood of cART initiation was associated with CD4 201-350 cells/μL, HIV RNA < 100,000 copies/mL, and with CD4 > 350 cells/μL (any HIV RNA level), compared to CD4 ≤ 200 cells/μL.
  
  
  CONCLUSIONS
  Availability of once-daily FDC-based regimens did not affect likelihood of cART initiation. Patient clinical characteristics appear to be more important predictors of cART initiation.
authors.affiliation: Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Mosen
authors.forename: Michael
authors.initials: M
authors.lastname: Horberg
authors.forename: Douglas
authors.initials: D
authors.lastname: Roblin
authors.forename: Christina M
authors.initials: CM
authors.lastname: Gullion
authors.forename: Richard
authors.initials: R
authors.lastname: Meenan
authors.forename: Wendy
authors.initials: W
authors.lastname: Leyden
authors.forename: Weiming
authors.initials: W
authors.lastname: Hu
references.citation: Clin Infect Dis. 2001 Dec 15;33(12):2055-60
references.pmid: 11700576
references.citation: AIDS Patient Care STDS. 2005 Dec;19(12):794-802
references.pmid: 16375611
references.citation: MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55
references.pmid: 12027060
references.citation: MMWR Recomm Rep. 1998 Apr 24;47(RR-5):43-82
references.pmid: 9572121
references.citation: Afr J Med Pract. 1998;5(2):79-104
references.pmid: 12322315
references.citation: Curr HIV/AIDS Rep. 2006 Jul;3(2):86-92
references.pmid: 16608665
references.citation: AIDS. 2001 Dec 7;15(18):2379-84
references.pmid: 11740188
references.citation: Pharmacotherapy. 2006 Aug;26(8):1111-33
references.pmid: 16863488
references.citation: Ann Intern Med. 2000 Jul 4;133(1):21-30
references.pmid: 10877736
references.citation: AIDS Patient Care STDS. 2005 Sep;19(9):563-76
references.pmid: 16164383
references.citation: J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):808-16
references.pmid: 15213564
references.citation: J HIV Ther. 2003 Feb;8(1):7-11
references.pmid: 12840708
references.citation: Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433
references.pmid: 12617573
references.citation: J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):106-14
references.pmid: 10935685
references.citation: JAMA. 2006 Aug 16;296(7):827-43
references.pmid: 16905788